Search

Your search keyword '"Sekiguchi, Kie"' showing total 12 results
Start Over Author "Sekiguchi, Kie"
12 results on '"Sekiguchi, Kie"'

3. WCN24-244 The utility of Indoxyl sulfate as a biomarker for early detection of CKD

Author

Hisano, Mizuki, primary, Abe, Takaya, additional, Sekiguchi, Kie, additional, Shiomi, Ei, additional, Ishii, Shuhei, additional, Matsuura, Tomohiko, additional, Maekawa, Shigekatsu, additional, Kato, Renpei, additional, Kanehira, Mistugu, additional, Takata, Ryo, additional, Sugimura, Jun, additional, Tanno, Kozo, additional, Abe, Toshikazu, additional, Tatsumi, Kenta, additional, and Obara, Wataru, additional

Published
2024
Full Text
View/download PDF

4. WCN24-866 THE TYPE OF HEPARIN USED FOR ANTICOAGULATION IN PATIENTS ON HEMODIALYSIS AFFECTS CARNITINE METABOLISM

Author

Sekiguchi, Kie, primary, Abe, Takaya, additional, Shiomi, Ei, additional, Ikarashi, Daiki, additional, Matsuura, Tomohiko, additional, Maekawa, Shigekatsu, additional, Kato, Renpei, additional, Kanehira, Mitsugu, additional, Takata, Ryo, additional, Sugimura, Jun, additional, Sekiguchi, Takashi, additional, and Obara, Wataru, additional

Published
2024
Full Text
View/download PDF

5. Abnormal carnitine metabolism in hemodialysis patients on different anticoagulants.

Author

Sekiguchi, Kie, Abe, Takaya, Shiomi, Ei, Ikarashi, Daiki, Matsuura, Tomohiko, Maekawa, Shigekatsu, Kato, Renpei, Kanehira, Mitsugu, Takata, Ryo, Sugimura, Jun, Sekiguchi, Takashi, and Obara, Wataru

Subjects
LOW-molecular-weight heparin, HEMODIALYSIS patients, CARNITINE, FREE fatty acids, ANTICOAGULANTS
Abstract

Introduction: We aimed to determine whether unfractionated heparin (UH) and low molecular weight heparin (LH) contribute to aberrant carnitine metabolism in patients receiving hemodialysis. Methods: The rate of increase in serum free fatty acids (FFAs) and the ratio of acylcarnitine to free carnitine (AC/FC) from before to after hemodialysis were determined in patients receiving UH and LH. Additionally, the effect of switching patients to UH from LH was examined. Results: AC/FC was significantly higher in the UH group. In addition, serum FFAs in that group increased to 0.825 ± 0.270 after dialysis from 0.172 ± 0.160 before dialysis, showing a positive correlation with AC/FC. Furthermore, AC/FC was observed to be significantly higher in patients who were switched to UH from LH at 3 months after the change. Conclusion: Compared with UH, LH has a lesser effect on lipid metabolism, suggesting that it also has a lesser effect on carnitine metabolism. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Prevalence of germline BRCA1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.

Author

Maekawa, Shigekatsu, Takata, Ryo, Sekiguchi, Kie, Kagabu, Masahiro, Toyoshima, Moe, Tamada, Shinji, Takahashi, Kenta, Ikarashi, Daiki, Matsuura, Tomohiko, Kato, Renpei, Kato, Yoichiro, Kanehira, Mitsugu, Sugimura, Jun, Abe, Takaya, Baba, Tsukasa, and Obara, Wataru

Published
2024
Full Text
View/download PDF

10. Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report

Author

MACHIDA, ARISA, primary, IKARASHI, DAIKI, additional, YANAGAWA, NAOKI, additional, SUZUK, MASAMICHI, additional, KAWAMURA, TATSUYA, additional, SEKIGUCHI, KIE, additional, TAKAHASHI, KENTA, additional, KATO, RENPEI, additional, MATSURA, TOMOHIKO, additional, MAEKAWA, SHIGEKATSU, additional, KANEHIRA, MITSUGU, additional, TAKATA, RYO, additional, SUGAI, TAMOTSU, additional, and OBARA, WATARU, additional

Published
2022
Full Text
View/download PDF

12. Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report.

Author

Machida A, Ikarashi D, Yanagawa N, Suzuki M, Kawamura T, Sekiguchi K, Takahashi K, Kato R, Matsura T, Maekawa S, Kanehira M, Takata R, Sugai T, and Obara W

Abstract

Background/aim: Surgical treatment of renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus is associated with high morbidity and mortality rates, therefore presurgical systemic therapies are required in order to improve the safety and feasibility of the surgical procedure by decreasing the thrombus level and burden. The efficacy of presurgical combination therapy of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) for advanced renal cell carcinoma with IVC thrombus remains unclear., Case Report: We report a case of a 69-year-old male with cT3bN0M0 locally advanced RCC. We successfully performed a less invasive nephrectomy with thrombectomy, because nivolumab plus cabozantinib administration remarkably reduced the primary tumor and IVC thrombus, resulting in complete pathological response, as assessed with perioperative immunohistochemistry., Conclusion: To the best of our knowledge, this is the first report showing that nephrectomy could be safely performed for RCC with IVC thrombus after presurgical nivolumab plus cabozantinib therapy, leading to pathological complete response., Competing Interests: The Authors declare no conflicts of interest., (Copyright 2023, International Institute of Anticancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results